Testosterone Therapy

Fewer than 1% of adults receiving exogenous testosterone for gender-confirming hormone therapy have a hematocrit level above the norm of 54%, according to data published in The Journal of Clinical Endocrinology & Metabolism.

Testosterone therapy may reduce HbA1c for men with type 2 diabetes and hypogonadism, according to a presenter at the European Association for the Study of Diabetes annual meeting.

The risk for developing diabetes in adults aged 65 years and older was lower in those who received 100 mg of aspirin daily, according to an analysis of the ASPREE study.

Testosterone undecanoate therapy may not confer long-term benefits for men with impaired glucose tolerance and normal testosterone levels, according to a follow-up survey of participants in the T4DM trial.

Transgender and gender-diverse adults who received testosterone therapy immediately instead of after a standard care waiting period of 3 months had greater reductions in gender dysphoria, depression and suicidality, according to study data.

CHICAGO — Older men with hypogonadism and high risk for cardiovascular disease who received testosterone therapy had similar rates of CV events as those who received placebo, according to findings from the TRAVERSE trial.

Testosterone replacement therapy may help improve body composition in men with hypogonadism and prediabetes, according to findings published in Andrology.

Nearly three-quarters of people using testosterone therapy for gender affirmation reported pelvic pain, according to findings of an online survey published in LGBT Health.

ATLANTA — Testosterone undecanoate therapy is associated with improved quality of life and reduced symptom severity in men with hypogonadism and type 2 diabetes, according to data presented at ENDO 2022.

Testosterone therapy was not associated with unexpected or rapid disease progression in a cohort of men with biochemical recurrence or metastatic prostate cancer, according to study findings.